Recently, the Category 1 innovative drug Sunvozertinib Tablets (Chinese trade name: 舒沃哲) of Dizal (Jiangsu) Pharmaceutical Co., Ltd is approved by China NMPA. This drug is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after platinum-containing chemotherapy, or are intolerant to platinum-containing chemotherapy, and have been confirmed to have an insertion mutation in the epidermal growth factor receptor (EGFR) exon 20 through testing.

Sunvozertinib is an EGFR tyrosine kinase inhibitor. The marketing of this drug provides a new treatment option for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR 20 exon insertion mutations.